A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Bristol-Myers Squibb
Bristol-Myers Squibb
Revolution Medicines, Inc.
Verastem, Inc.
Anova Innovation Limited
Lokon Pharma AB
Ascentage Pharma Group Inc.
Suzhou Transcenta Therapeutics Co., Ltd.
University Health Network, Toronto
Thomas Jefferson University
Incyte Corporation
Bristol-Myers Squibb
Ability Pharmaceuticals SL
Verastem, Inc.
Lisata Therapeutics, Inc.
Prestige Biopharma Limited
NGM Biopharmaceuticals, Inc
Precision Biologics, Inc
InxMed (Shanghai) Co., Ltd.
UNC Lineberger Comprehensive Cancer Center
iOnctura
Herlev Hospital
BeyondBio Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chinese PLA General Hospital
Cyteir Therapeutics, Inc.
Shanghai YingLi Pharmaceutical Co. Ltd.
BioNTech SE
University of Oxford
Harbin Medical University
Shanghai Zhongshan Hospital
State University of New York - Downstate Medical Center
Fudan University
Nagoya University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Jiangsu HengRui Medicine Co., Ltd.
University of Texas Southwestern Medical Center
Barbara Ann Karmanos Cancer Institute
MedImmune LLC
Changhai Hospital
Canadian Cancer Trials Group
Barbara Ann Karmanos Cancer Institute
Hoosier Cancer Research Network
HonorHealth Research Institute
Kyntra Bio
Mereo BioPharma
Eli Lilly and Company
National Cancer Institute (NCI)
Chinese PLA General Hospital
M.D. Anderson Cancer Center
Lumos Pharma